A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Janssen Research & Development, LLC
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT01484275
First received: December 1, 2011
Last updated: July 14, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients with high-risk smoldering multiple myeloma (SMM).


Condition Intervention Phase
High-risk Smoldering Multiple Myeloma
Drug: Siltuximab
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • One-year progression-free survival (PFS) rate [ Time Frame: One year after randomization of last patient ] [ Designated as safety issue: No ]
    Defined by CRAB - IMWG (calcium, renal, anemia, and bone lesions - International Myeloma Working Group) criteria.


Secondary Outcome Measures:
  • Progression-free survival (PFS) [ Time Frame: Up to approximately 4 years after randomization of last patient ] [ Designated as safety issue: No ]
    Based on CRAB criteria.

  • Progressive Disease (PD) indicator rate [ Time Frame: 6 months after randomization of last patient ] [ Designated as safety issue: No ]
    Novel composite endpoint, built from potential early signs of progression to multiple myeloma.

  • European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 (EORTC QLQ C30) [ Time Frame: Up to approximately 4 years after randomization of last patient ] [ Designated as safety issue: No ]
    The questionnaire includes 9 scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single-item scales (dyspnea, insomnia, anorexia, constipation, diarrhea and financial impact) and single-item global health and quality of life scales.

  • Brief Pain Inventory (worst pain item) [ Time Frame: Up to approximately 4 years after randomization of last patient ] [ Designated as safety issue: No ]
    Refers to the "worst" pain the patient has experienced over the past 24 hours.

  • Changes in clinical laboratory values [ Time Frame: Up to approximately 4 years after randomization of last patient ] [ Designated as safety issue: Yes ]
  • Number of participants experiencing adverse events [ Time Frame: Up to approximately 4 years after randomization of last patient ] [ Designated as safety issue: Yes ]
  • Overall survival [ Time Frame: Approximately 4 years after randomization of last patient ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: March 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Siltuximab
Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Drug: Siltuximab
Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Placebo Comparator: Placebo
Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Drug: Placebo
Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.

Detailed Description:

This is a randomized (treatment assigned by chance), double-blind (neither patient nor investigator know which treatment is given), multicenter study to evaluate the safety and efficacy of siltuximab compared with placebo in patients with high-risk SMM (defined as bone marrow plasma cells >=10% and either serum monoclonal protein >=3 g/dL, or abnormal free light chain ratio <0.126 or >8 and serum M-protein <3 g/dL but >=1 g/dL). Approximately 100 patients will receive either siltuximab or placebo by intravenous (IV, injection into a vein) infusion every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study (approximately 4 years after randomization of the last patient). Efficacy, pharmacokinetics, immunogenicity, and potential biomarkers will be assessed at time points defined in the protocol. Patient reported outcomes (European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30, Brief Pain Inventory [worst pain], Non-Chemotherapy Anemia Symptom Scale) will be administered before any procedure or treatment at each visit. Patient safety will be monitored throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of smoldering multiple myeloma (SMM) for <4 years
  • Diagnosis of high-risk SMM (defined as bone marrow plasma cells >=10% and either serum monoclonal protein >=3 g/dL, or abnormal free light chain ratio <0.126 or >8 and serum M-protein <3 g/dL but >=1 g/dL)
  • Patients must be within certain limits for protocol-specified laboratory tests
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Women not of childbearing potential must be postmenopausal, permanently sterilized, or otherwise incapable of pregnancy
  • Women of childbearing potential must agree to use adequate birth control measures and agree to not donate eggs for the purpose of assisted reproduction during the study and for 3 months after receiving the last dose of study agent, and must have a negative pregnancy test at screening
  • Men must agree to use a double-barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study agent

Exclusion Criteria:

  • Having symptomatic multiple myeloma, defined by any of the following (if due to myeloma): lytic bone lesions, severe osteopenia (low bone density), pathologic fractures, hypercalcemia (too much calcium in the blood), kidney insufficiency; symptomatic hyperviscosity of the blood, or recurrent serious bacterial infections such as pneumonia
  • Primary systemic amyloid light (AL) chain amyloidosis (a build-up of amyloid light chain proteins in the blood)
  • Prior or concurrent exposure to approved or investigational multiple myeloma treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates, denosumab), or steroids (not exceeding 10 mg prednisone per day or equivalent) are only allowed if given in a stable dose and for a nonmalignant condition; concurrent treatment with erythropoietin-stimulating agents (ESAs) are not allowed.)
  • Prior exposure to agents targeting interleukin 6 (IL 6) or the IL 6 receptor
  • Other malignancy within the past 3 years, except for the following, if treated and not active: basal cell or nonmetastatic (non-spreading) squamous cell carcinoma of the skin, cervical carcinoma or International Federation of Gynecology and Obstetrics Stage 1 carcinoma of the cervix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01484275

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

  Hide Study Locations
Locations
United States, Alabama
Withdrawn
Muscle Shoals, Alabama, United States
United States, Arkansas
Withdrawn
Little Rock, Arkansas, United States
United States, Connecticut
Withdrawn
Norwich, Connecticut, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Kansas
Withdrawn
Westwood, Kansas, United States
United States, Maryland
Withdrawn
Bethesda, Maryland, United States
Completed
Rockville, Maryland, United States
United States, Michigan
Withdrawn
Ann Arbor, Michigan, United States
Recruiting
Detroit, Michigan, United States
United States, Mississippi
Withdrawn
Jackson, Mississippi, United States
United States, New Mexico
Withdrawn
Albuquerque, New Mexico, United States
United States, New York
Recruiting
New York, New York, United States
United States, North Carolina
Withdrawn
Durham, North Carolina, United States
United States, Ohio
Withdrawn
Cleveland, Ohio, United States
Withdrawn
Columbus, Ohio, United States
United States, Pennsylvania
Completed
Kittanning, Pennsylvania, United States
Recruiting
Philadelphia, Pennsylvania, United States
United States, South Carolina
Recruiting
Greenville, South Carolina, United States
United States, Tennessee
Withdrawn
Germantown, Tennessee, United States
United States, Texas
Recruiting
Dallas, Texas, United States
Withdrawn
Houston, Texas, United States
United States, Virginia
Withdrawn
Newport News, Virginia, United States
United States, Wisconsin
Withdrawn
Madison, Wisconsin, United States
Withdrawn
Sheboygan, Wisconsin, United States
Australia
Recruiting
Camperdown, Australia
Recruiting
East Melbourne, Australia
Recruiting
Randwick, Australia
Belgium
Recruiting
Antwerpen, Belgium
Recruiting
Brussels, Belgium
Recruiting
Gent, Belgium
France
Completed
Dijon, France
Recruiting
Nantes Cedex 1, France
Recruiting
Tours, France
Recruiting
Villejuif, France
Germany
Recruiting
Berlin, Germany
Suspended
Duisburg, Germany
Recruiting
Hamburg, Germany
Recruiting
Heidelberg, Germany
Withdrawn
Mainz, Germany
Withdrawn
Münster, Germany
Withdrawn
Würzburg, Germany
Greece
Not yet recruiting
Athens, Greece
Israel
Recruiting
Ashkelon, Israel
Withdrawn
Haifa, Israel
Recruiting
Jerusalem, Israel
Recruiting
Nahariya, Israel
Recruiting
Netanya, Israel
Recruiting
Petach Tikva, Israel
Korea, Republic of
Recruiting
Daejeon, Korea, Republic of
Suspended
Seognam-Si, Kyungki-Do, Korea, Republic of
Recruiting
Seoul, Korea, Republic of
Spain
Recruiting
Barcelona, Spain
Recruiting
Barcleona, Spain
Recruiting
Madrid, Spain
Recruiting
Salamanca, Spain
Recruiting
Valencia, Spain
Sweden
Completed
Göteborg, Sweden
Completed
Linkoping, Sweden
Withdrawn
Malmö, Sweden
Completed
Stockholm, Sweden
Withdrawn
Uppsala, Sweden
United Kingdom
Withdrawn
Glasgow, United Kingdom
Recruiting
London, United Kingdom
Withdrawn
London, United Kingdom
Recruiting
Manchester, United Kingdom
Withdrawn
Nottingham, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Additional Information:
No publications provided

Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01484275     History of Changes
Obsolete Identifiers: NCT01563666
Other Study ID Numbers: CR100755, CNTO328SMM2001, 2011-001735-22
Study First Received: December 1, 2011
Last Updated: July 14, 2014
Health Authority: United States: Food and Drug Administration
Germany: Ethics Commission
United States: Federal Government
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Janssen Research & Development, LLC:
High-risk smoldering multiple myeloma
Multiple myeloma
Siltuximab

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014